Brookfield Asset Management is considering a €7 billion (approximately $10 billion) bid to acquire Grifols, a Spanish pharmaceutical company specializing in blood plasma-based products.

Brookfield is contemplating a public tender offer at €10.5 per share, which is below Grifols' recent market closing price of €11.125.

Grifols has experienced a 30 percent decline in market value since January 2024.